Apollon Wealth Management LLC Purchases 10,233 Shares of Johnson & Johnson $JNJ

Apollon Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 171,511 shares of the company's stock after purchasing an additional 10,233 shares during the quarter. Apollon Wealth Management LLC's holdings in Johnson & Johnson were worth $45,406,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JNJ. Level Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Level Wealth Management LLC now owns 1,244 shares of the company's stock valued at $329,000 after acquiring an additional 63 shares during the period. Access Investment Management LLC boosted its stake in shares of Johnson & Johnson by 12.2% in the 3rd quarter. Access Investment Management LLC now owns 5,659 shares of the company's stock valued at $1,498,000 after purchasing an additional 615 shares in the last quarter. Tower View Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 74.6% in the 3rd quarter. Tower View Wealth Management LLC now owns 1,660 shares of the company's stock valued at $439,000 after purchasing an additional 709 shares in the last quarter. Pullen Investment Management LLC grew its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Pullen Investment Management LLC now owns 6,959 shares of the company's stock worth $1,842,000 after purchasing an additional 46 shares during the last quarter. Finally, Leeward Financial Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $201,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $271.17 on Thursday. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The firm has a market cap of $652.78 billion, a PE ratio of 41.09, a price-to-earnings-growth ratio of 2.61 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The business has a fifty day moving average of $265.60 and a 200-day moving average of $246.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is presently 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
• Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
• Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
• Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
• Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson

Insiders Place Their Bets

In other news, EVP Elizabeth Forminard sold 15,918 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 64,515 shares of company stock valued at $17,271,766. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 29th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $275.00 to $287.00 and gave the stock an "overweight" rating in a research note on Friday, October 16th. Guggenheim reaffirmed a "buy" rating and set a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. Finally, Citigroup raised their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.